A new triple system DNA-Nanosilver-Berberine for cancer therapy

15Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The isoquinoline quaternary alkaloid Berberine possesses a variety of pharmacological properties that suggests its promising application for an anticancer delivery system design utilizing its ability to intercalate DNA. In the current work, we have investigated the effects of Berberine on the human T cell leukemia cell line in vitro. Fluorescent microscopy of leukemic cells revealed Berberine nuclear localization. The results showed that Berberine inhibited leukemic cell growth in a time- and dose-dependent manner, that was associated with reactive oxygen species production intensification and caspase 3/7 activity increase with followed apoptosis induction. Berberine was used as a toxic and phototoxic agent for triple system synthesis along with DNA as a carrier and nanosilver as a plasmonic accelerator of Berberine electronic transitions and high energy emission absorbent centers. The proposed method allows to obtain the complex of DNA with Berberine molecules and silver nanoparticles. The optical properties of free components as well as their various combinations, including the final triple system DNA-Nanosilver-Berberine, were investigated. Obtained results support the possibility to use the triple system DNA-Nanosilver-Berberine as an alternative therapeutic agent for cancer treatment.

Cite

CITATION STYLE

APA

Grebinyk, A., Yashchuk, V., Bashmakova, N., Gryn, D., Hagemann, T., Naumenko, A., … Frohme, M. (2019). A new triple system DNA-Nanosilver-Berberine for cancer therapy. Applied Nanoscience (Switzerland), 9(5), 945–956. https://doi.org/10.1007/s13204-018-0688-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free